Three drugs accepted for use in NHS Scotland, but six rejected
Filgrastim (Nivestim; Hospira) is one of three drugs that have been approved for use in NHS Scotland following the Scottish Medicines Consortium’s latest round of appraisals (February 2011). The medicine is accepted for use for its licensed indications, which relate to neutropenia.
Capsaicin cutaneous patches (Qutenza; Astellas) are accepted for restricted use for the treatment of peripheral neuropathic pain in non-diabetic adults, either alone or in combination with other medicinal products for pain.
Treatment with the patches must be under the supervision of a specialist in pain management, and is restricted to adults with post-herpetic neuralgia who have not achieved adequate pain relief from, or have not tolerated, conventional first- and second-line treatments.
Rituximab (Mabthera; Roche) is also accepted for restricted use for the maintenance treatment of follicular lymphoma in patients responding to induction therapy with the drug plus chemotherapy.
Six medicines were not recommended by the consortium. Golimumab (Simponi; Merck, Sharp and Dohme) was rejected for treatment of psoriatic arthritis in adults with poor response to disease-modifying antirheumatic drugs because its manufacturer did not provide a sufficiently robust economic case.
The miconazole muco-adhesive buccal tablet (Loramyc; Therabel Pharma) was rejected for use for the treatment of oropharyngeal candidiasis in immunocompromised patients because the SMC was not convinced by the clinical and economic cases presented.
Trastuzumab (Herceptin; Roche) was rejected for use for the treatment of patients with HER2-positive metastatic adenocarcinoma of the stomach because it was not considered value for money.
Other medicines not accepted were colesevelam (Cholestagel; Genzyme Therapeutics) for hypercholesterolaemia, fenticonazole (Ginoxin; Recordati Pharmaceuticals) and ivabradine (Procoralan; Servier Laboratories) because the marketing authorisation holders did not make submissions to the SMC.
Citation: The Pharmaceutical Journal URI: 11068280
Recommended from Pharmaceutical Press